These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34080290)

  • 1. Identification and assessment of PLK1/2/3/4 in lung adenocarcinoma and lung squamous cell carcinoma: Evidence from methylation profile.
    Deng S; Lu X; Zhang Z; Meng R; Li M; Xia S
    J Cell Mol Med; 2021 Jul; 25(14):6652-6663. PubMed ID: 34080290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analyses of expressions and prognostic values of Polo-like kinases in non-small cell lung cancer.
    Zeng Y; Li N; Liu W; Zeng M; Cheng J; Huang J
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2447-2460. PubMed ID: 32627077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53-Dependent and cell specific epigenetic regulation of the polo-like kinases under oxidative stress.
    Ward A; Hudson JW
    PLoS One; 2014; 9(1):e87918. PubMed ID: 24498222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1.
    Liu J; Lu KH; Liu ZL; Sun M; De W; Wang ZX
    BMC Cancer; 2012 Nov; 12():519. PubMed ID: 23151088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated bioinformatics analysis reveals CDK1 and PLK1 as potential therapeutic targets of lung adenocarcinoma.
    Li S; Li H; Cao Y; Geng H; Ren F; Li K; Dai C; Li N
    Medicine (Baltimore); 2021 Aug; 100(32):e26474. PubMed ID: 34397869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies.
    Syed N; Smith P; Sullivan A; Spender LC; Dyer M; Karran L; O'Nions J; Allday M; Hoffmann I; Crawford D; Griffin B; Farrell PJ; Crook T
    Blood; 2006 Jan; 107(1):250-6. PubMed ID: 16160013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
    Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
    Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
    Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
    Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LSD1 Inhibition Attenuates Tumor Growth by Disrupting PLK1 Mitotic Pathway.
    Dalvi PS; Macheleidt IF; Lim SY; Meemboor S; Müller M; Eischeid-Scholz H; Schaefer SC; Buettner R; Klein S; Odenthal M
    Mol Cancer Res; 2019 Jun; 17(6):1326-1337. PubMed ID: 30760542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-mitotic functions of polo-like kinases in cancer cells.
    Raab CA; Raab M; Becker S; Strebhardt K
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of polo-like kinase 1 (PLK1) protein predicts the survival of patients with gastric carcinoma.
    Kanaji S; Saito H; Tsujitani S; Matsumoto S; Tatebe S; Kondo A; Ozaki M; Ito H; Ikeguchi M
    Oncology; 2006; 70(2):126-33. PubMed ID: 16645325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-296-5p suppresses cell viability by directly targeting PLK1 in non-small cell lung cancer.
    Xu C; Li S; Chen T; Hu H; Ding C; Xu Z; Chen J; Liu Z; Lei Z; Zhang HT; Li C; Zhao J
    Oncol Rep; 2016 Jan; 35(1):497-503. PubMed ID: 26549165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.
    McCarroll JA; Dwarte T; Baigude H; Dang J; Yang L; Erlich RB; Kimpton K; Teo J; Sagnella SM; Akerfeldt MC; Liu J; Phillips PA; Rana TM; Kavallaris M
    Oncotarget; 2015 May; 6(14):12020-34. PubMed ID: 25557168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic effect of Polo-like kinase 1 expression in human gastric carcinomas.
    Jang YJ; Kim YS; Kim WH
    Int J Oncol; 2006 Sep; 29(3):589-94. PubMed ID: 16865274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The kinase PLK1 promotes the development of
    Kong Y; Allison DB; Zhang Q; He D; Li Y; Mao F; Li C; Li Z; Zhang Y; Wang J; Wang C; Brainson CF; Liu X
    Sci Signal; 2022 Oct; 15(754):eabj4009. PubMed ID: 36194647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylation of synucleins by members of the Polo-like kinase family.
    Mbefo MK; Paleologou KE; Boucharaba A; Oueslati A; Schell H; Fournier M; Olschewski D; Yin G; Zweckstetter M; Masliah E; Kahle PJ; Hirling H; Lashuel HA
    J Biol Chem; 2010 Jan; 285(4):2807-22. PubMed ID: 19889641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The RNA helicase/transcriptional co-regulator, p68 (DDX5), stimulates expression of oncogenic protein kinase, Polo-like kinase-1 (PLK1), and is associated with elevated PLK1 levels in human breast cancers.
    Iyer RS; Nicol SM; Quinlan PR; Thompson AM; Meek DW; Fuller-Pace FV
    Cell Cycle; 2014; 13(9):1413-23. PubMed ID: 24626184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PLK1-associated microRNAs are correlated with pediatric medulloblastoma prognosis.
    Pezuk JA; Brassesco MS; de Oliveira RS; Machado HR; Neder L; Scrideli CA; Tone LG
    Childs Nerv Syst; 2017 Apr; 33(4):609-615. PubMed ID: 28283778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom.
    King SI; Purdie CA; Bray SE; Quinlan PR; Jordan LB; Thompson AM; Meek DW
    Breast Cancer Res; 2012 Mar; 14(2):R40. PubMed ID: 22405092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic inactivation implies a tumor suppressor function in hematologic malignancies for Polo-like kinase 2 but not Polo-like kinase 3.
    Smith P; Syed N; Crook T
    Cell Cycle; 2006 Jun; 5(12):1262-4. PubMed ID: 16868416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.